CDX2 Antibody [CDX2/1690] | 33-767

CDX2 Antibody [CDX2/1690] | 33-767 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: Amino acids 150-249 from the human protein were used as the immunogen for this CDX2 antibody.

Research Area: Homeostasis, Stem Cell

Tested Application: WB, IHC-P, Flow, IF

Application: Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
IF: 1-2 ug/ml
IHC (FFPE) : 0.5-1 ug/ml for 30 min at RT
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the CDX2 antibody to be titered up or down for optimal performance.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein G affinity chromatography

Clonality: Monoclonal

Clone: CDX2/1690

Isotype: IgG2a, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: CDX2 Antibody: CDX3, CDX-3, CDX3, Homeobox protein CDX-2

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: The intestine-specific transcription factors CDX1 and CDX2 are important for directing intestinal development, differentiation, proliferation and maintenance of the intestinal phenotype. CDX2 protein expression has been seen in GI carcinomas. Anti-CDX2 has been useful to establish GI origin of metastatic adenocarcinomas and carcinoids and is especially useful to distinguish metastatic colorectal adenocarcinoma from lung adenocarcinoma. However, mucinous carcinomas of the ovary also express CDX2 protein. It limits the usefulness of this marker in the distinction of metastatic colorectal adenocarcinoma from mucinous carcinoma of the ovary.